Christina Johnson to TNF-Related Apoptosis-Inducing Ligand
This is a "connection" page, showing publications Christina Johnson has written about TNF-Related Apoptosis-Inducing Ligand.
Connection Strength
1.678
-
STAT-6 mediates TRAIL induced RANK ligand expression in stromal/preosteoblast cells. Bone. 2015 Feb; 71:137-44.
Score: 0.239
-
TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol. 2011 Jun 14; 8(8):417-27.
Score: 0.189
-
Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins. J Urol. 2009 Sep; 182(3):1178-85.
Score: 0.166
-
Combination therapy with TRAIL: Recent developments and potential pitfalls. Cancer Biol Ther. 2009 Jan; 8(1):81-3.
Score: 0.160
-
Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene. 2009 Feb 26; 28(8):1132-41.
Score: 0.160
-
Transformation, translation and TRAIL: an unexpected intersection. Cytokine Growth Factor Rev. 2008 Apr; 19(2):167-72.
Score: 0.151
-
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. 2007 Mar; 14(3):327-34.
Score: 0.139
-
Illuminating TRAIL gene therapy. Cancer Biol Ther. 2006 Nov; 5(11):1521-2.
Score: 0.138
-
Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. Mol Pharm. 2009 Sep-Oct; 6(5):1612-9.
Score: 0.042
-
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic Biol Med. 2007 Nov 01; 43(9):1313-21.
Score: 0.036
-
Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. Cancer Biol Ther. 2006 Dec; 5(12):1618-23.
Score: 0.035
-
In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther. 2006 Mar; 13(3):281-9.
Score: 0.033
-
Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein. Mol Cancer Ther. 2005 Sep; 4(9):1320-7.
Score: 0.032
-
Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer. 2005 Jan 07; 5:2.
Score: 0.030
-
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003 Nov; 10(11):814-22.
Score: 0.028
-
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol Ther. 2003 May-Jun; 2(3):283-90.
Score: 0.027
-
Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther. 2002 Sep-Oct; 1(5):520-7.
Score: 0.026
-
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72.
Score: 0.025
-
The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36.
Score: 0.023